442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy
oleh: Jennifer Sims, Patrick Brune, René Hoet, Emmanuel Valentin, LE Suong, Sophie Agaugué, Paul Frohna
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.